Take a deeper dive

Webinar | Drug Development Considerations for Dermatology:
More Than Skin Deep

This webinar covers an introduction to topical drug development and other important clinical pharmacology considerations for products for dermatological conditions. Topically applied drugs often follow different requirements for pharmacokinetic (PK) assessment than drugs administered orally or intravenously. During the webinar, issues specific for topical drug development will be discussed including various requirements, such as the maximal usage trial (MuST) for a successful application.

At the end of this webinar attendees should have a better understanding of:

  • Why does formulation matter?
  • How to collect and interpret pharmacokinetics for topically applied products
  • Regulatory requirements and clinical pharmacology considerations

Meet the Speaker

Elizabeth (Betty) Hussey, Pharm.D.
Vice President, Clinical Pharmacology & Pharmacokinetics

Dr. Hussey has over 30 years of extensive leadership and experience in drug development, clinical development, clinical pharmacology, and pharmacokinetics across multiple therapeutic areas and all phases of development. Dr. Hussey’s primary therapeutic area experience includes dermatology, metabolic diseases, CNS (headaches), antivirals, and anti-infectives with focus on early proof-of-concept.

Explore Our Blog

What are Good Laboratory Practices (GLP) for Nonclinical Studies?

Good Laboratory Practices (GLP) provide regulations and the standard by which drug safety studies are conducted in nonclinical animal studies.…

Read More

Benefits of Utilizing the 505(b)(2) Pathway for Prodrugs

Over the past decade, at least 30 prodrugs have been approved by the US Food and Drug Administration (FDA). It…

Read More

Understanding CDISC SEND Data and How to Be Compliant

Nonclinical study data submitted to the FDA must align with the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation…

Read More